ebulised pentoxifylline for the prevention of chronic lung disease in extremely preterm infants

Phase 2

• Conditions: Bronchopulmonary dysplasia; Premature birth; Respiratory - Other respiratory disorders / diseases; Reproductive Health and Childbirth - Complications of newborn

• Registration Number: ACTRN12611000145909
• Lead Sponsor: King Edward Memorial Hospital, NCC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-02-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Preterm infants < 28 w GA will be eligible for enrolment if they require mechanical ventilation greater than or equal to 30% supplemental oxygen at 72 – 168 h of life and if written informed parental consent is given.

Exclusion Criteria

Congenital malformations of the thorax (e.g. congenital diaphragmatic hernia, congenital cystic adenomatoid malformation of the lung, esophageal atresia)
Major cardiac malformations. (Infants with persistent ductus arteriosus or hemodynamically non-significant atrial or ventricular septal defect may be included in the trial).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration on supplemental oxygen (hours) at 40 week Post menstrual age.[At 40 weeks post menstrual age.]

Secondary Outcome Measures

Name	Time	Method
Bronchopulmonary dysplasia or death[At 40 weeks post menstrual age];Mortality to hospital discharge[At discharge];Duration of hospital stay[At discharge]